It’s helpful to select therapies early in the phase-one YourPDX functional testing process to avoid delays during the phase-two pharmacology study. Certis will need to know how many study arms will be included to determine the number of orthotopic patient-derived xenograft (O-PDX) replicates to create. We enroll five fully-tumored mouse avatars in each arm of the clinical research study, including the control arm. By way of example: if five different therapeutic options are chosen, that is a 6-arm study (5 plus 1 control); 30 fully tumored mouse avatars would be required to conduct the study. We generally engraft 20% more mice than are needed to ensure we have enough mouse avatars when it comes time to begin dosing.